Loading...
•
Dec 31, 2025
Zai Lab Q4 2025 Earnings Report
Zai Lab reported 17% year-over-year revenue growth in the fourth quarter of 2025, driven by strong product sales, while narrowing its net loss compared to the prior year period.
Key Takeaways
Zai Lab delivered 17% year-over-year product revenue growth in Q4 2025, primarily driven by XACDURO and NUZYRA, while reducing net loss as revenue growth outpaced operating expense increases and foreign currency gains contributed positively.
Total revenue increased 17% year-over-year to 127597000 in Q4 2025.
Net loss narrowed to 50409000 from 81684000 in the prior year quarter.
XACDURO revenue grew 225% year-over-year, contributing meaningfully to growth.
Operating loss remained elevated at 69406000 despite revenue expansion.
Revenue by Segment
Forward Guidance
The company plans to advance multiple late-stage oncology and immunology programs in 2026 while preparing for new commercial launches to support sustained revenue growth.
Positive Outlook
- Advancing three registration-enabling studies for zocilurtatug pelitecan by end of 2026.
- Planned KarXT commercial launch in China in first half of 2026.
- Multiple pivotal data readouts expected in 2026.
- Potential NMPA approvals for Tisotumab Vedotin and TTFields.
- Expansion of global immunology and oncology pipeline programs.
Challenges Ahead
- Continued operating losses expected as pipeline investment continues.
- Supply limitations previously impacted XACDURO growth.
- Dependence on regulatory approvals for near-term catalysts.
- Exposure to foreign currency fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...